

# EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	5	lamotrigene	US-PGPUB; USPAT; USOCR	OR	ON	2007/11/29 12:55
L3	9	lamotrigene	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/11/29 12:55
L4	26137	particles same specific adj surface adj area	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/11/29 12:56
L5	207	L4 and pharmaceutical adj composition	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/11/29 12:56
L6	0	L5 and L3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/11/29 12:56
L7	2	lamotrigene.dlm	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/11/29 13:07
L9	2	("5861179") or ("20040121003"),PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/11/29 13:14
L11	1	("20040043996"),PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/11/29 13:15
S1	0	lamotrigene same partide adj size	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/08/24 07:32
S2	7	lamotrigene	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/04/04 15:24
S3	23310	particles same specific adj surface adj area	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/08/23 17:04

# EAST Search History

S4	163	S3 and pharmaceutical adj composition	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/08/23 17:51
S5	0	lamotrigene same Teva adj Pharmaceutical?	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/08/23 17:54
S6	0	lamotrigene same Teva	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/08/23 17:52
S7	1	("3090693"),PN.	US-PGPUB; USPAT	OR	OFF	2006/08/23 18:21
S8	1	("5861179"),PN.	US-PGPUB; USPAT	OR	OFF	2006/08/23 18:21
S9	0	bet near particle adj size near surface adj area	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/08/24 07:33
S10	1134	particle adj size near surface adj area	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/08/24 07:43
S11	3	S10 and BET adj measure?	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/08/24 12:25
S12	3	("4847249") or ("5942510") or ("5861179"),PN.	US-PGPUB; USPAT	OR	OFF	2006/08/24 12:31
S13	1	("4602017"),PN.	US-PGPUB; USPAT	OR	OFF	2006/08/24 15:06
S14	1	("0021121"),PN.	US-PGPUB; USPAT	OR	OFF	2006/08/24 15:08
S15	1	("4486354"),PN.	US-PGPUB; USPAT	OR	OFF	2006/08/24 15:08
S16	7	("4486354") or ("5643591") or ("4602017") or ("6639072") or ("5925755") or ("5942510") or ("5861179"),PN.	US-PGPUB; USPAT	OR	OFF	2006/08/25 09:16
S17	4552	"424/489" CCLS	US-PGPUB; USPAT; USOCR	OR	ON	2007/04/04 15:20
S18	3731	S17 and @ad <= "20030801"	US-PGPUB; USPAT; USOCR	OR	ON	2007/04/04 16:07

# EAST Search History

S19	160	((JUDITH) near2 (ARONHIME)). INV.	US-PGPUB; USPAT; USOCR	OR	ON	2007/04/04 15:49
S20	5	((GUY) near2 (SAMBURSKI)). INV.	US-PGPUB; USPAT; USOCR	OR	ON	2007/04/04 15:20
S21	88	((JUDITH) near2 (ARONHIME)). INV.	EPO; JPO; DERWENT	OR	ON	2007/04/04 15:21
S22	6	((GUY) near2 (SAMBURSKI)). INV.	EPO; JPO; DERWENT	OR	ON	2007/04/04 15:21
S23	697	"514742". CCLS.	US-PGPUB; USPAT; USOCR	OR	ON	2007/04/04 15:21
S24	509	S23 and @ad<="20030801"	US-PGPUB; USPAT; USOCR	OR	ON	2007/11/29 12:54
S25	0	"3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/04/04 15:44
S26	8	"LAMOTRIGINE"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/04/04 15:29
S27	0	"6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/04/04 15:44
S28	0	S18 and lamotrigine	US-PGPUB; USPAT; USOCR	OR	ON	2007/04/04 15:49
S29	0	S23 and lamotrigine	US-PGPUB; USPAT; USOCR	OR	ON	2007/04/04 15:51
S30	1	("6861426"). PM.	US-PGPUB; USPAT	OR	OFF	2007/04/04 16:06
S31	1	lamotrigene.dlm	US-PGPUB; USPAT; DERWENT	OR	ON	2007/04/04 16:07
S32	2	lamotrigene.tl	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/04/04 16:07

# EAST Search History

S33	65	lamotrigine.tl	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/04/04 16:07
S34	202	lamotrigene.dlm	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/04/04 16:07
S35	12	S33 and @ad<="20030801"	US-PGPUB; USPAT; USOCR	OR	ON	2007/04/04 16:14
S36	91	S34 and @ad<="20030801"	US-PGPUB; USPAT; USOCR	OR	ON	2007/04/04 16:08
S37	0	("5861179"). URPN.	USPAT	OR	ON	2007/04/04 16:09
S38	1	("5912345"). URPN.	USPAT	OR	ON	2007/04/04 16:10
S39	38	S36 and partit??	US-PGPUB; USPAT; USOCR	OR	ON	2007/04/04 16:15

10/511987 Lamotrigene

=> d his

(FILE 'HOME' ENTERED AT 13:03:43 ON 29 NOV 2007)

FILE 'REGISTRY' ENTERED AT 13:03:52 ON 29 NOV 2007

L1 1 S 84057-84-1/RN

FILE 'HCAPLUS' ENTERED AT 13:04:14 ON 29 NOV 2007

L2 1461 S L1

L3 278076 S PARTICLE (A) SIZE

L4 35036 S SPECIFIC (A) SURFACE (A) AREA

L5 5893 S L3 AND L4

L6 0 S L5 AND L2

L7 1 S L4 AND L2

L8 12 S L2 AND L3

FILE 'STNGUIDE' ENTERED AT 13:06:40 ON 29 NOV 2007

L9 0 S PARTICLE (A) DIAMETER

L10 0 S L1 AND PARTICLE?

FILE 'HCAPLUS' ENTERED AT 13:12:23 ON 29 NOV 2007

L11 36158 S PARTICLE (A) DIAMETER

L12 2 S L11 AND L1

L13 22 S L1 AND PARTICLE?

10/511987 Lamotrigene

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAMLL1621

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS EXPRESS	19	SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:03:43 ON 29 NOV 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:03:52 ON 29 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 NOV 2007 HIGHEST RN 956214-95-2

DICTIONARY FILE UPDATES: 28 NOV 2007 HIGHEST RN 956214-95-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s 84057-84-1/rn

L1 1 84057-84-1/RN

=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 84057-84-1 REGISTRY

ED Entered STN: 16 Nov 1984

CN 1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)- (CA INDEX NAME)

OTHER NAMES:


CN 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine

CN BW 430C

CN Lamictal

10/511987 Lamotrigene

CN Lamictal XR  
CN Lamotrigin  
CN Lamotrigine  
CN LTG  
MF C9 H7 Cl2 N5  
CI COM  
SR European Union (EU)  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,  
CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSChem, DDFU,  
DRUGU, EMBASE, IMSCoSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA,  
MEDLINE, MRCK\*, PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS\*,  
SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, WHO  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1455 REFERENCES IN FILE CA (1907 TO DATE)  
19 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
1461 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file hcapl

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
2.40	2.61

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 13:04:14 ON 29 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

10/511987 Lamotrigene

FILE COVERS 1907 - 29 Nov 2007 VOL 147 ISS 23

FILE LAST UPDATED: 28 Nov 2007 (20071128/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1

L2 1461 L1

=> s particle (a) size

776681 PARTICLE

848337 PARTICLES

1289988 PARTICLE

(PARTICLE OR PARTICLES)

1106547 SIZE

147334 SIZES

1185663 SIZE

(SIZE OR SIZES)

L3 278076 PARTICLE (A) SIZE

=> s specific (a) surface (a) area

1452945 SPECIFIC

1674 SPECIFICS

1454437 SPECIFIC

(SPECIFIC OR SPECIFICS)

309660 SP

8685 SPS

317904 SP

(SP OR SPS)

1732319 SPECIFIC

(SPECIFIC OR SP)

2512405 SURFACE

466379 SURFACES

2701775 SURFACE

(SURFACE OR SURFACES)

686283 AREA

291714 AREAS

913801 AREA

(AREA OR AREAS)

L4 35036 SPECIFIC (A) SURFACE (A) AREA

=> s l3 and l4

L5 5893 L3 AND L4

=> d his

(FILE 'HOME' ENTERED AT 13:03:43 ON 29 NOV 2007)

FILE 'REGISTRY' ENTERED AT 13:03:52 ON 29 NOV 2007

L1 1 S 84057-84-1/RN

FILE 'HCAPLUS' ENTERED AT 13:04:14 ON 29 NOV 2007

L2 1461 S L1

L3 278076 S PARTICLE (A) SIZE

L4 35036 S SPECIFIC (A) SURFACE (A) AREA

10/511987 Lamotrigene

L5 5893 S L3 AND L4

=> s 15 and 12

L6 0 L5 AND L2

=> s 14 and 12

L7 1 L4 AND L2

=> d ibib abs

L7 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:875073 HCAPLUS

DOCUMENT NUMBER: 139:354488

TITLE: Pharmaceutical composition containing lamotrigine particles of defined morphology

INVENTOR(S): Aronhime, Judith; Samburski, Guy

PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003090693	A2	20031106	WO 2003-US13002	20030423
WO 2003090693	A3	20040108		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2483103	A1	20031106	CA 2003-2483103	20030423
AU 2003234240	A1	20031110	AU 2003-234240	20030423
EP 1496864	A2	20050119	EP 2003-728552	20030423
EP 1496864	B1	20070321		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
AT 357217	T	20070415	AT 2003-728552	20030423
ES 2282628	T3	20071016	ES 2003-3728552	20030423
US 2005238724	A1	20051027	US 2004-511987	20041021
PRIORITY APPLN. INFO.:			US 2002-374923P	P 20020423
			WO 2003-US13002	W 20030423

AB The present invention provides a pharmaceutical composition comprising a plurality of lamotrigine particles having a sp. surface area of from about two to about three and a half meters per g. Pharmaceutical compns. falling within the surface area criteria for the lamotrigine particles include those having a particle diameter equal to or less than about 100  $\mu\text{m}$ , preferably about 50  $\mu\text{m}$ , and most preferably 10  $\mu\text{m}$ . The pharmaceutical composition can be formulated into a wide variety



of dosage forms for treatment of seizures.

=> s 12 and 13

L8 12 L2 AND L3

=> d ibib 1-12 abs

L8 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:874559 HCAPLUS

DOCUMENT NUMBER: 147:220128

TITLE: Drug delivery systems comprising weakly basic drugs and organic acids

INVENTOR(S): Venkatesh, Gopi M.

PATENT ASSIGNEE(S): Eurand, Inc., USA

SOURCE: PCT Int. Appl., 58pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007090091	A2	20070809	WO 2007-US61237	20070129
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2007196491	A1	20070823	US 2007-668408	20070129
PRIORITY APPLN. INFO.:			US 2006-762766P	P 20060127
AB	A pharmaceutical dosage form such as a capsule, a conventional or orally disintegrating tablet capable of delivering a nitrogen (N)-containing therapeutic agent having a pKa in the range of from about 5 to 14 into the body in a sustained-released fashion, in order to be suitable for a twice- or once-daily dosing regimen, comprises at least one organic acid, which solubilizes the therapeutic agent the drug prior to releasing it into the hostile intestinal environment wherein said weakly basic drug is practically insol. The unit dosage form is composed of a multitude of multicoated particulates (i.e., immediate-release beads, sustained-release beads and/or one or more timed, pulsatile-release bead populations) is designed in such a way that said weakly basic drug and said organic acid do not come into close contact during processing and/or storage for in-situ formation of acid addition compds. while ensuring that the acid is not depleted prior to completion of the drug release.			
	Dipyrimadole immediate-release beads (obtained by coating sustained-release coated fumaric acid cores) were barrier-coated by spraying a solution of 90/10 EC-10/TEC (tri-Et citrate) at 5-10% by weight and dried in the Glatt for 10 min to obtain sustained-release beads.			

L8 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:728812 HCAPLUS  
DOCUMENT NUMBER: 147:125588  
TITLE: Mouth dissolving pharmaceutical composition and  
process for preparing the same  
INVENTOR(S): Kashid, Namdev; Mukherji, Gour  
PATENT ASSIGNEE(S): Jubilant Organosys Limited, India  
SOURCE: PCT Int. Appl., 25pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007074472	A2	20070705	WO 2006-IN319	20060830
WO 2007074472	A3	20070816		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: IN 2005-DE3482 A 20051227

AB Disclosed herein is an orally disintegrating and/or dissolving oral pharmaceutical composition, comprising one or more active pharmaceutical ingredients, one or more fillers having particle size of 100  $\mu$  or above, a high and desirable amount of SiO<sub>2</sub>, one or more disintegrating agents, optionally effervescent couple, wherein said composition has good organoleptic properties like desired mouth feel and fast oral disintegration time.

L8 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:475563 HCAPLUS  
DOCUMENT NUMBER: 146:474685  
TITLE: Isocratic reversed-phase HPLC for simultaneous separation and determination of seven antiepileptic drugs and two of their active metabolites in human plasma  
AUTHOR(S): Ma, Chun-Lai; Jiao, Zheng; Jie, Yang; Shi, Xiao-Jin  
CORPORATE SOURCE: Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, Peop. Rep. China  
SOURCE: Chromatographia (2007), 65(5/6), 267-275  
CODEN: CHRGB7; ISSN: 0009-5893  
PUBLISHER: Vieweg Verlag/GWV Fachverlage GmbH  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB A simple reversed-phase HPLC method was developed for the simultaneous determination of the antiepileptic drugs (AEDs) zonisamide (ZNS), primidone (PRI),

Lamotrigine (LTG), phenobarbital (PB), phenytoin (PHT), oxcarbazepine (OXC), and carbamazepine (CBZ) and 2 of their active metabolites, monohydroxycarbamazepine (MHD) and carbamazepine 10,11-epoxide (CBZE), in human plasma. Plasma (100  $\mu$ L) was pretreated by deproteinization with 300  $\mu$ L methanol containing 20  $\mu$ g mL<sup>-1</sup> propranolol hydrochloride as internal standard. HPLC was performed on a C8 column (4.6 mm  $\times$  250 mm; particle size 5  $\mu$ m) with methanol-acetonitrile-0.1% trifluoroacetic acid, 235:120:645 (volume/volume), as mobile phase at a flow rate of 1.5 mL min<sup>-1</sup>. ZNS, OXC, and CBZ were monitored by UV detection at 235 nm, and PRI, LTG, MHD, PB, PHT, and CBZE by UV detection at 215 nm. Relationships between response and concentration were linear over the concentration ranges 1-80  $\mu$ g mL<sup>-1</sup> for ZNS, 5-50  $\mu$ g mL<sup>-1</sup> for PRI, 1-25  $\mu$ g mL<sup>-1</sup> for LTG, 1-50  $\mu$ g mL<sup>-1</sup> for MHD, 5-100  $\mu$ g mL<sup>-1</sup> for PB, 1-10  $\mu$ g mL<sup>-1</sup> for CBZE, 0.5-25  $\mu$ g mL<sup>-1</sup> for OXC, 1-50  $\mu$ g mL<sup>-1</sup> for PHT, and 1-25  $\mu$ g mL<sup>-1</sup> for CBZ. Intra- and interday reproducibility were adequate (coeffs. of variation were  $\leq$ 11.6%) and absolute recovery ranged from 95.2  $\pm$  6.13 to 107.7  $\pm$  7.76% for all the analytes; for the IS, recovery was 98.69  $\pm$  1.12%. The method was accurate, reproducible, convenient, and suitable for therapeutic monitoring of the 9 analytes.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1241184 HCAPLUS

DOCUMENT NUMBER: 143:483161

TITLE: Mouth dissolvable and meltable, and water dispersable delivery formulation for antiepileptics

INVENTOR(S): Chakravorty, Saibal; Hariharan, V.

PATENT ASSIGNEE(S): Rpg Life Sciences Limited, India

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005109990	A2	20051124	WO 2005-IN101	20050404
WO 2005109990	A3	20060706		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
IN 2004MU00419	A	20060303	IN 2004-MU419	20040406
AU 2005244329	A1	20051124	AU 2005-244329	20050404
CA 2562213	A1	20051124	CA 2005-2562213	20050404
EP 1737405	A2	20070103	EP 2005-768079	20050404

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,  
HR, LV, MK, YU

IN 2005MU00426 A 20070525 IN 2005-MU426 20050404  
PRIORITY APPLN. INFO.: IN 2004-MU419 A 20040406  
WO 2005-IN101 W 20050404

AB A mouth dissolvable and meltable, and water dispersible delivery system for oral administration consisting of an antiepileptic drug, one or more swelling agents, one or more of fillers, one or more of disintegrating agents, and one or more of binders is disclosed. The swelling agent is powdered cellulose, filler is spray dried mannitol, disintegrating agent is crosslinked polyvinyl pyrrolidone and binder is maltodextrin. This system optionally comprises one or more of other excipients selected from the group comprising lubricants, sweeteners and flavoring agent.

L8 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:493490 HCAPLUS  
DOCUMENT NUMBER: 143:32332  
TITLE: Water dispersible tablet  
INVENTOR(S): Gupta, Vinod Kumar; Vaya, Navin; Sougata, Pramanick  
PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India  
SOURCE: PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051350	A2	20050609	WO 2004-IN312	20041007
WO 2005051350	A3	20050818		
WO 2005051350	B1	20050929		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

IN 2003MU01128 A 20070504 IN 2003-MU1128 20031028  
PRIORITY APPLN. INFO.: IN 2003-MU1128 A 20031028

AB This invention relates to a water-dispersible formulation of an active pharmaceutical ingredient or pharmaceutically acceptable salt hereof and one or more adjuvants without the use of swellable clay. More particularly, the invention comprises a dispersible formulation of anti-epileptic drug - lamotrigine. This invention further relates to a process for the preparation of said formulation.

L8 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:366596 HCAPLUS  
DOCUMENT NUMBER: 143:65658  
TITLE: Optimisation and use of water-in-oil MEEKC in

pharmaceutical analysis  
AUTHOR(S): Broderick, Margo; Donegan, Sheila; Power, Joe; Altria, Kevin  
CORPORATE SOURCE: Waterford Institute of Technology, Department of Chemical and Life Sciences, Waterford, Ire.  
SOURCE: Journal of Pharmaceutical and Biomedical Analysis (2005), 37(5), 877-884  
CODEN: JPBADA; ISSN: 0731-7085  
PUBLISHER: Elsevier B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Water-in-oil microemulsion electrokinetic chromatog. was applied to the separation of a range of acids, bases and neutrals and is especially suitable for very water-insol. drug compds. A number of operating parameters were evaluated. An optimized set of operating conditions allowed separation of a range of pharmaceutical formulations containing water-insol. compds. A number of novel applications for W/O microemulsions were developed and ability to quantify drug contents in tablets and a cream was shown with good precision, detector linearity and accuracy. Comparison of obtained data with those determined from a HPLC method showed acceptable agreement.  
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:325504 HCAPLUS  
DOCUMENT NUMBER: 142:379390  
TITLE: Pharmaceutical formulations comprising microparticles with improved dispersibility, suspendability or wettability  
INVENTOR(S): Chickering, Donald E.; Reese, Shaina; Narasimhan, Sridhar; Straub, Julie A.; Bernstein, Howard; Altreuter, David; Huang, Eric K.; Brito, Luis A.; Jain, Rajeev A.  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 324,550.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005079138	A1	20050414	US 2004-955261	20040930
US 2004121003	A1	20040624	US 2002-324558	20021219
PRIORITY APPLN. INFO.:			US 2002-324558	A2 20021219

AB Methods are provided for making a dry powder blend pharmaceutical formulation, comprising the steps of: (a) providing microparticles which comprise a pharmaceutical agent; (b) blending the microparticles with at least one excipient in the form of particles to form a powder blend; and (c) jet milling the powder blend to form a dry powder blend pharmaceutical formulation having improved dispersibility, suspendability, or wettability as compared to the microparticles of step (a) or the powder blend of step (b). The method can further include dispersing the dry powder blend

pharmaceutical formulation in a liquid pharmaceutically acceptable vehicle to make an formulation suitable for injection. Alternatively, the method can further include processing the dry powder blend pharmaceutical formulation into a solid oral dosage form. In one embodiment, the microparticles of step (a) are formed by a solvent precipitation or crystallization

process. PLGA microspheres containing mannitol and Tween 80 having number average

particle size of 1.96  $\mu\text{m}$ , and volume average

particle size of 4.04  $\mu\text{m}$  were prepared. The jet milling provided significant particle deagglomeration.

L8 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:216629 HCAPLUS  
 DOCUMENT NUMBER: 142:285200  
 TITLE: Nanoparticles for drug delivery  
 INVENTOR(S): Turos, Edward; Shim, Jeung-Yeop  
 PATENT ASSIGNEE(S): University of South Florida, USA  
 SOURCE: PCT Int. Appl., 144 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020933	A2	20050310	WO 2004-US28995	20040902
WO 2005020933	A3	20050609		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2007190160	A1	20070816	US 2006-570461	20060302
PRIORITY APPLN. INFO.:			US 2003-499904P	P 20030902
			US 2003-500750P	P 20030904
			US 2004-568746P	P 20040506
			WO 2004-US28995	W 20040902

AB This invention relates to a unique process for the preparation of polymeric nanoparticles with target mols. bonded to the surface of the particles and having sizes of up to 1000 nm, preferably 1-400 nm, more preferably 1-200 nm, that are dispersed homogeneously in aqueous solution. To accomplish the above objective, the polymeric nanoparticles of the subject invention are prepared using a novel technique of microemulsion polymerization. The resulting aqueous solution of polymeric nanoparticles is comprised of about 1-100 parts per weight of water or buffer, about 1-80 parts per weight of polymeric nanoparticles, which the bioactive mols. are conjugated, about 0.001-10 parts per weight of emulsifier, and about 0.00001-5 parts per weight of radical initiator based

on the weight of the solution In the method of this invention, the target drug/target substance is covalently bonded to the polymeric nanoparticles to secure them from outer intervention in vivo or cell culture in vitro until they are exposed at the target site within the cell. Nanoparticles of ethylacrylate-N-methylthiolated 3-lactam copolymer were prepared by a radical polymerization using potassium persulfate as the initiator and the sodium salt of dodecyl sulfate as the surfactant. The particle size was 40-80 nm. The antibacterial activity of the nanoparticles is shown.

L8 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:430288 HCAPLUS

DOCUMENT NUMBER: 140:429017

TITLE: Drug condensation aerosols and kits

INVENTOR(S): Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Lu, Amy T.; Myers, Daniel J.; Rabinowitz, Joshua D.; Wensley, Martin J.

PATENT ASSIGNEE(S): Alexza Molecular Delivery Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 84 pp., Cont.-in-part of U.S. Ser. No. 633,877.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 34

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004099269	A1	20040527	US 2003-718982	20031120
US 7090830	B2	20060815		
US 2003051728	A1	20030320	US 2001-57198	20011026
US 2003015197	A1	20030123	US 2002-146088	20020513
US 2003017115	A1	20030123	US 2002-146516	20020513
US 6737042	B2	20040518		
US 2003035776	A1	20030220	US 2002-146515	20020513
US 6682716	B2	20040127		
US 2003209240	A1	20031113	US 2002-146086	20020513
CN 1990057	A	20070704	CN 2007-10002060	20020513
US 2003007933	A1	20030109	US 2002-150267	20020515
US 6797259	B2	20040928		
US 2003007934	A1	20030109	US 2002-150268	20020515
US 6780399	B2	20040824		
US 2003091511	A1	20030515	US 2002-150056	20020515
US 6805853	B2	20041019		
AU 2002309948	A1	20030526	AU 2002-309948	20020515
US 2003017117	A1	20030123	US 2002-151596	20020516
US 6855310	B2	20050215		
US 2003206869	A1	20031106	US 2002-151626	20020516
US 6783753	B2	20040831		
US 2003017116	A1	20030123	US 2002-150857	20020517
US 6716415	B2	20040406		
US 2003021753	A1	20030130	US 2002-150591	20020517
US 6780400	B2	20040824		
US 2003005924	A1	20030109	US 2002-152652	20020520
US 6740307	B2	20040525		
US 2003012740	A1	20030116	US 2002-153139	20020520

US 6814954	B2	20041109		
US 2003017118	A1	20030123	US 2002-152639	20020520
US 6716416	B2	20040406		
US 2003021754	A1	20030130	US 2002-152640	20020520
US 6743415	B2	20040601		
US 2003012737	A1	20030116	US 2002-153311	20020521
US 6884408	B2	20050426		
US 2003015189	A1	20030123	US 2002-153831	20020521
US 6740308	B2	20040525		
US 2003017119	A1	20030123	US 2002-153839	20020521
US 6776978	B2	20040817		
US 2003032638	A1	20030213	US 2002-153313	20020521
US 2003005925	A1	20030109	US 2002-155621	20020522
US 6759029	B2	20040706		
US 2003012738	A1	20030116	US 2002-155373	20020522
US 6737043	B2	20040518		
US 2003017120	A1	20030123	US 2002-155703	20020522
US 6803031	B2	20041012		
US 2003021755	A1	20030130	US 2002-155705	20020522
US 6805854	B2	20041019		
US 2003000518	A1	20030102	US 2002-155097	20020523
US 6716417	B2	20040406		
US 2003015190	A1	20030123	US 2002-154594	20020523
US 6740309	B2	20040525		
US 2003017114	A1	20030123	US 2002-154765	20020523
US 6814955	B2	20041109		
US 2003118512	A1	20030626	US 2002-280315	20021025
WO 2003045484	A2	20030605	WO 2002-US37491	20021121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002364508	A1	20030610	AU 2002-364508	20021121
US 2003138382	A1	20030724	US 2002-302010	20021121
US 7078016	B2	20060718		
US 2003138508	A1	20030724	US 2002-322227	20021217
US 2007031340	A1	20070208	US 2003-633877	20030804
US 2004126326	A1	20040701	US 2003-734902	20031212
US 7029658	B2	20060418		
US 2004127481	A1	20040701	US 2003-735198	20031212
US 7008615	B2	20060307		
US 2004126327	A1	20040701	US 2003-735199	20031212
US 7070761	B2	20060704		
US 2004127490	A1	20040701	US 2003-735495	20031212
US 7018619	B2	20060328		
US 2004126329	A1	20040701	US 2003-735497	20031212
US 7070762	B2	20060704		
US 2004156788	A1	20040812	US 2003-749535	20031230
US 7115250	B2	20061003		
US 2004156789	A1	20040812	US 2003-749536	20031230
US 7094392	B2	20060822		



US 2004156790	A1	20040812	US 2003-749783	20031230
US 7078019	B2	20060718		
US 2004156791	A1	20040812	US 2003-750303	20031230
US 7078020	B2	20060718		
US 2005075273	A1	20050407	US 2003-749539	20031230
US 7078018	B2	20060718		
US 2005089479	A1	20050428	US 2003-749537	20031230
US 7078017	B2	20060718		
US 2004184996	A1	20040923	US 2004-766279	20040127
US 7087217	B2	20060808		
US 2004191179	A1	20040930	US 2004-766566	20040127
US 7060254	B2	20060613		
US 2004191181	A1	20040930	US 2004-766634	20040127
US 7070763	B2	20060704		
US 2004191182	A1	20040930	US 2004-766647	20040127
US 7070764	B2	20060704		
US 2004228807	A1	20041118	US 2004-766149	20040127
US 7087216	B2	20060808		
US 2004184997	A1	20040923	US 2004-767115	20040128
US 7052679	B2	20060530		
US 2004184998	A1	20040923	US 2004-768205	20040129
US 7070765	B2	20060704		
US 2004184999	A1	20040923	US 2004-768220	20040129
US 7063830	B2	20060620		
US 2004185000	A1	20040923	US 2004-768293	20040129
US 7067114	B2	20060627		
US 2004185003	A1	20040923	US 2004-769157	20040129
US 7060255	B2	20060613		
US 2004185004	A1	20040923	US 2004-769197	20040129
US 7063831	B2	20060620		
US 2004202617	A1	20041014	US 2004-768281	20040129
US 7169378	B2	20070130		
US 2004185001	A1	20040923	US 2004-769046	20040130
US 7070766	B2	20060704		
US 2004185002	A1	20040923	US 2004-769051	20040130
US 7033575	B2	20060425		
US 2004161385	A1	20040819	US 2004-775586	20040209
US 7048909	B2	20060523		
US 2004167228	A1	20040826	US 2004-775583	20040209
US 7018620	B2	20060328		
US 2004185005	A1	20040923	US 2004-813721	20040331
US 7022312	B2	20060404		
US 2004186130	A1	20040923	US 2004-813722	20040331
US 7063832	B2	20060620		
US 2004191183	A1	20040930	US 2004-814690	20040331
US 7014841	B2	20060321		
US 2004191184	A1	20040930	US 2004-814998	20040331
US 7108847	B2	20060919		
US 2004185006	A1	20040923	US 2004-815527	20040401
US 6994843	B2	20060207		
US 2004185007	A1	20040923	US 2004-816407	20040401
US 7011820	B2	20060314		
US 2004185008	A1	20040923	US 2004-816567	20040401
US 7052680	B2	20060530		
US 2004191185	A1	20040930	US 2004-816492	20040401
US 7008616	B2	20060307		
US 2006153779	A1	20060713	US 2006-370628	20060307

US 2006177382	A1	20060810	US 2006-398383	20060404
US 2006216243	A1	20060928	US 2006-439475	20060524
US 2006216244	A1	20060928	US 2006-442917	20060530
US 2006233718	A1	20061019	US 2006-451852	20060613
US 2006233719	A1	20061019	US 2006-451853	20060613
US 2006239936	A1	20061026	US 2006-454573	20060616
US 2006246011	A1	20061102	US 2006-479361	20060630
US 2006246012	A1	20061102	US 2006-479509	20060630
US 2006251587	A1	20061109	US 2006-479892	20060630
US 2006251588	A1	20061109	US 2006-481279	20060705
US 2006257328	A1	20061116	US 2006-488302	20060718
US 2006257329	A1	20061116	US 2006-488943	20060718
US 2006280692	A1	20061214	US 2006-488932	20060718
US 2006269487	A1	20061130	US 2006-501246	20060807
US 2006286042	A1	20061221	US 2006-500735	20060807
US 2007122353	A1	20070531	US 2006-504419	20060815
US 2006286043	A1	20061221	US 2006-507986	20060822
US 2007014737	A1	20070118	US 2006-523685	20060919
US 2007178052	A1	20070802	US 2007-621397	20070109
AU 2007207865	A1	20070906	AU 2007-207865	20070816
PRIORITY APPLN. INFO.:-			US 2001-57197	A2 20011026
			US 2001-57198	A2 20011026
			US 2001-345882P	P 20011109
			US 2001-332165P	P 20011121
			US 2001-332279P	P 20011121
			US 2001-332280P	P 20011121
			US 2001-342066P	P 20011218
			US 2002-50056	B2 20020114
			US 2002-57098	A2 20020123
			US 2002-371457P	P 20020409
			US 2002-146080	A2 20020513
			US 2002-146086	A2 20020513
			US 2002-146088	A2 20020513
			US 2002-146515	A2 20020513
			US 2002-146516	A2 20020513
			US 2002-150056	A2 20020515
			US 2002-150267	A2 20020515
			US 2002-150268	A2 20020515
			US 2002-151596	A2 20020516
			US 2002-151626	A2 20020516
			US 2002-150591	A2 20020517
			US 2002-150857	A2 20020517
			US 2002-152639	A2 20020520
			US 2002-152640	A2 20020520
			US 2002-152652	A2 20020520
			US 2002-153139	A2 20020520
			US 2002-153311	A2 20020521
			US 2002-153313	B2 20020521
			US 2002-153831	A2 20020521
			US 2002-153839	A2 20020521
			US 2002-155373	A2 20020522
			US 2002-155621	A2 20020522
			US 2002-155703	A2 20020522
			US 2002-155705	A2 20020522
			US 2002-154594	A2 20020523
			US 2002-154765	A2 20020523
			US 2002-155097	A2 20020523

US 2002-412068P	P 20020918
US 2002-280315	A2 20021025
US 2002-302010	A2 20021121
US 2002-302614	A2 20021121
US 2002-322227	A2 20021217
US 2003-633876	A2 20030804
US 2003-633877	A2 20030804
US 2001-294203P	P 20010524
US 2001-296225P	P 20010605
US 2001-317479P	P 20010905
US 2001-335049P	P 20011030
US 2001-336218P	P 20011030
US 2001-345145P	P 20011109
US 2001-345876P	P 20011109
AU 2002-311923	A3 20020513
CN 2002-811406	A3 20020513
WO 2002-US15820	W 20020515
WO 2002-US37491	W 20021121
US 2003-718982	A1 20031120
US 2003-734902	A1 20031212
US 2003-735198	A1 20031212
US 2003-735199	A1 20031212
US 2003-735495	A1 20031212
US 2003-735497	A1 20031212
US 2003-749535	A1 20031230
US 2003-749536	A1 20031230
US 2003-749537	A1 20031230
US 2003-749539	A1 20031230
US 2003-749783	A1 20031230
US 2003-750303	A1 20031230
US 2004-766149	A1 20040127
US 2004-766279	A1 20040127
US 2004-766566	A1 20040127
US 2004-766634	A1 20040127
US 2004-766647	A1 20040127
US 2004-768220	A1 20040129
US 2004-768281	A1 20040129
US 2004-769157	A1 20040129
US 2004-769046	A1 20040130
US 2004-775586	A1 20040209
US 2004-813721	A1 20040331
US 2004-814998	A1 20040331
US 2004-816492	A1 20040401
US 2004-816567	A1 20040401

AB The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3  $\mu$ . The aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20  $\mu$ m, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically ED of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols

and kits. For example, acebutolol (MW 336, m.p. 123°, oral dose 400 mg), a  $\beta$ -adrenergic blocker (cardiovascular agent), was coated on a stainless steel cylinder (8 cm). The drug (0.89 mg) was applied to the substrate, for a calculated drug film thickness of 1.1  $\mu$ m. The substrate was heated at 20.5 V and purity of the drug aerosol particles was determined to be 98.9%; 0.53 mg was recovered from the filter after vaporization, for a percent yield of 59.6%. A total mass of 0.81 mg was recovered from the test apparatus and substrate, for a total recovery of 91%. High speed photographs were taken as the drug-coated substrate was heated to monitor visually formation of a thermal vapor. The photographs showed that a thermal vapor was initially visible 30 ms after heating was initiated, with the majority of the thermal vapor formed by 130 ms. Generation of the thermal vapor was complete by 500 ms.

L8 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:464546 HCAPLUS

DOCUMENT NUMBER: 125:96152

TITLE: Pharmaceutical granules comprising lamotrigine

INVENTOR(S): Hiskett, Simon Philip; Taylor, Susan Ann

PATENT ASSIGNEE(S): Wellcome Foundation Ltd., UK

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9617611	A1	19960613	WO 1995-GB2865	19951207
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2207284	A1	19960613	CA 1995-2207284	19951207
AU 9641211	A	19960626	AU 1996-41211	19951207
AU 696406	B2	19980910		
EP 797441	A1	19971001	EP 1995-939352	19951207
EP 797441	B1	20020227		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
CN 1174505	A	19980225	CN 1995-197473	19951207
HU 77367	A2	19980330	HU 1997-2196	19951207
BR 9509975	A	19980609	BR 1995-9975	19951207
JP 10510255	T	19981006	JP 1995-517420	19951207
JP 2977284	B2	19991115		
RU 2160106	C2	20001210	RU 1997-111870	19951207
AT 213633	T	20020315	AT 1995-939352	19951207
ES 2172600	T3	20021001	ES 1995-939352	19951207
FI 9702434	A	19970609	FI 1997-2434	19970606
NO 9702623	A	19970806	NO 1997-2623	19970606
US 5861179	A	19990119	US 1997-849070	19970626
PRIORITY APPLN. INFO.:			GB 1994-24766	A 19941207
			WO 1995-GB2865	W 19951207

AB A pharmaceutical formulation comprises: (a) from 0.5 to 50% by weight of lamotrigine or a pharmaceutically acceptable acid addition salt thereof, (b) from 15 to 50% by weight of lactose, (c) from 15 to 50% by weight of starch, (d) from 0.5 to 15% by weight of crystalline cellulose, and (e) from 5 to 15% by weight of polyvinylpyrrolidone, and which is in the form of a free-flowing powder of granules having the following properties: (1) no granules have a particle size of greater than 850  $\mu\text{m}$ , (2) at least 90% by weight of the granules have a particle size of from 75 to 850  $\mu\text{m}$ , (3) the granules disintegrate within 30 min according to the Disintegration Test of The Pharmacopoeia of Japan, twelfth edition, 1991, and (i.v.) of at least 90% by weight of the lamotrigine or lamotrigine salt in the granules dissolves within 30 min when the granules are subjected to the dissoln. test, method 2 (paddle method) of the Pharmacopoeia of Japan, twelfth edition, 1991. Formulation of various granules are disclosed.

L8 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:440156 HCAPLUS

DOCUMENT NUMBER: 119:40156

TITLE: New method for the determination of four antiepileptic drugs in human plasma by high performance liquid chromatography

AUTHOR(S): Meyler, M.; Kelly, M. T.; Smyth, M. R.

CORPORATE SOURCE: Sch. Chem. Sci., Dublin City Univ., Dublin, Ire.

SOURCE: Chromatographia (1993), 36, 27-32

CODEN: CHRGB7; ISSN: 0009-5893

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The concurrent administration of several antiepileptic drugs for the treatment of seizure disorders has become common practice. Lamotrigine is a new antiepileptic given in combination with other antiepileptic drugs, but which is not routinely measured in clin. labs. An isocratic high-performance liquid chromatog. method is described for the simultaneous measuring lamotrigine, carbamazepine, phenobarbital and phenytoin within 10 min. The chromatog. system used an Hichrom Spherisorb CN column (20 cm x 4 mm, i.d., 5  $\mu\text{m}$  particle size), a  $\mu$ Bondapak CN precolumn, and a mobile phase consisting of methanol : acetonitrile : 5 mM sodium acetate (5 : 20 : 75 by volume, pH adjusted to 6.3 with acetic acid). BWA 725C was used as internal standard. The drugs were extracted from

200

$\mu\text{L}$  of plasma with Et acetate, acetonitrile and 5 mM sodium acetate. After evaporation of the organic layer and reconstitution in mobile phase, 25  $\mu\text{L}$  of extract was eluted with mobile phase at a flow rate of 1.2 mL/min. The eluted drugs were detected by their absorption at 205 nm and quantified from their peak heights. The method was found to be rapid, relatively simple to perform and sufficiently sensitive to determine each drug over its entire therapeutic range. Lower limits of detection varied from 50-100 ng/mL, absolute recoveries from 93-98%, and mean intra- and inter-assay CVs were <3.0%.

L8 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:93715 HCAPLUS

DOCUMENT NUMBER: 118:93715

TITLE: A liquid chromatographic assay using a high-speed column for the determination of lamotrigine, a new

antiepileptic drug, in human plasma  
AUTHOR(S): Fazio, A.; Artesi, C.; Russo, M.; Trio, R.; Oteri, G.;  
Pisani, F.  
CORPORATE SOURCE: 1st Neurol. Clin., Univ. Messina, Messina, Italy  
SOURCE: Therapeutic Drug Monitoring (1992), 14(6), 509-12  
CODEN: TDMODV; ISSN: 0163-4356  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB A sensitive, specific and rapid liquid-chromatog. method for the determination  
of the new antiepileptic drug lamotrigine (LTG) in human plasma is described.  
The method involves the use of a com. available 3- $\mu$ m particle  
size normal-phase column and a microflow-cell-equipped UV  
detector. Extraction is carried out with Et acetate after alkalization on a  
100- $\mu$ L plasma sample containing LTG and 3,5-diamino-6-(2-methoxyphenyl)-  
1,2,4-triazine as internal standard. The residue is reconstituted with 50  
 $\mu$ L of ethanol, and 5  $\mu$ L of the final solution is injected into the  
column. Elution is carried out at 34° using n-hexane/absolute  
ethanol/35% ammonia (80:20:0.25 by volume) as mobile phase at a flow rate of  
2.0 mL/min.. Detection is at 313 nm. The chromatog. separation requires <3 min  
and the sensitivity limit is <0.01 mg/L. Recovery is 88-96.2%, whereas  
within-day and day-to-day coeffs. of variation are between 4.1 and 7.7%.

=&gt; fil stng

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

47.19

49.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-10.14

-10.14

FILE 'STNGUIDE' ENTERED AT 13:06:40 ON 29 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Nov 23, 2007 (20071123/UP).

=&gt; d his

(FILE 'HOME' ENTERED AT 13:03:43 ON 29 NOV 2007)

FILE 'REGISTRY' ENTERED AT 13:03:52 ON 29 NOV 2007

L1 1 S 84057-84-1/RN

FILE 'HCAPLUS' ENTERED AT 13:04:14 ON 29 NOV 2007

L2 1461 S L1

L3 278076 S PARTICLE (A) SIZE

L4 35036 S SPECIFIC (A) SURFACE (A) AREA

L5 5893 S L3 AND L4

L6 0 S L5 AND L2

L7 1 S L4 AND L2

L8 12 S L2 AND L3

FILE 'STNGUIDE' ENTERED AT 13:06:40 ON 29 NOV 2007

=> s particle (a) diameter

2 PARTICLE  
8 PARTICLES  
9 PARTICLE  
(PARTICLE OR PARTICLES)  
0 DIAMETER

L9 0 PARTICLE (A) DIAMETER

=> s l1 and particle?

'RN' IS NOT A VALID FIELD CODE

0 84057-84-1/RN  
9 PARTICLE?

L10 0 L1 AND PARTICLE?

=> file hcapl

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.60	50.40

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-10.14

CA SUBSCRIBER PRICE

FILE 'HCAPLUS' ENTERED AT 13:12:23 ON 29 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Nov 2007 VOL 147 ISS 23

FILE LAST UPDATED: 28 Nov 2007 (20071128/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s particle (a) diameter

776681 PARTICLE  
848337 PARTICLES  
1289988 PARTICLE  
(PARTICLE OR PARTICLES)  
35909 DIAMETER  
3014 DIAMETERS  
38295 DIAMETER  
(DIAMETER OR DIAMETERS)

10/511987 Lamotrigene

448958 DIAM  
51663 DIAMS  
483587 DIAM  
(DIAM OR DIAMS)

512551 DIAMETER  
(DIAMETER OR DIAM)

L11 36158 PARTICLE (A) DIAMETER

=> s l11 and l1

1461 L1

L12 2 L11 AND L1

=> d ibib abs 1-2

L12 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:991477 HCAPLUS

DOCUMENT NUMBER: 140:31517

TITLE: Controlled release formulation of lamotrigine

INVENTOR(S): Nadkarni, Sunil Sadanand

PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104192	A2	20031218	WO 2003-IN213	20030606
WO 2003104192	A3	20040311		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004043996	A1	20040304	US 2003-452772	20030602
CA 2488868	A1	20031218	CA 2003-2488868	20030606
AU 2003267808	A1	20031222	AU 2003-267808	20030606
BR 2003011701	A	20050308	BR 2003-11701	20030606
EP 1513535	A2	20050316	EP 2003-748504	20030606
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
IN 2004MN00051	A	20050624	IN 2004-MN51	20040120
IN 2004MN00393	A	20050429	IN 2004-MN393	20040719
PRIORITY APPLN. INFO.:			US 2002-386795P	P 20020607
			WO 2003-IN213	W 20030606
			IN 2004-MN51	A3 20040120
AB	Rapidly disintegrating multiparticulate controlled-release formulations of lamotrigine having an improved pharmacokinetic profile and improved patient compliance, and process of preparing the formulations are described. The formulations comprise pelleted cores covered with one or more			



different rate-controlling polymeric membrane(s). It provides better control of blood plasma levels than conventional tablet formulations that is administered once or more times a day. For example, granules (core particles, diam. of 0.15 to 0.30 mm) were prepared using a fluidized bed processor from 750 g of microcryst. cellulose and a bulk liquid containing lamotrigine 900.00 g, hydroxypropyl Me cellulose 545.45 g, and water 13.20 kg. The 1500 g of the drug granules (core particles) were spray coated with a rate-controlling coating membrane composition containing Eudragit RS PO 163.84 g, Eudragit RL PO 8.617 g, tri-Et citrate 34.5 g, talc 55.52 g, methylene chloride 997.5 g, and iso-Pr alc. 1671.25 g to obtain controlled-release particles. The controlled-release particles prepared were filled into capsules (50 mg/capsule) and showed better pharmacokinetic profile than the conventional tablets.

L12 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:875073 HCAPLUS

DOCUMENT NUMBER: 139:354488

TITLE: Pharmaceutical composition containing lamotrigine particles of defined morphology

INVENTOR(S): Aronhime, Judith; Samburski, Guy

PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003090693	A2	20031106	WO 2003-US13002	20030423
WO 2003090693	A3	20040108		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2483103	A1	20031106	CA 2003-2483103	20030423
AU 2003234240	A1	20031110	AU 2003-234240	20030423
EP 1496864	A2	20050119	EP 2003-728552	20030423
EP 1496864	B1	20070321		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
AT 357217	T	20070415	AT 2003-728552	20030423
ES 2282628	T3	20071016	ES 2003-3728552	20030423
US 2005238724	A1	20051027	US 2004-511987	20041021
PRIORITY APPLN. INFO.:			US 2002-374923P	P 20020423
			WO 2003-US13002	W 20030423

AB The present invention provides a pharmaceutical composition comprising a plurality of lamotrigine particles having a sp. surface area of from about

two to about three and a half meters per g. Pharmaceutical compns. falling within the surface area criteria for the lamotrigine particles include those having a particle diam. equal to or less than about 100  $\mu\text{m}$ , preferably about 50  $\mu\text{m}$ , and most preferably 10  $\mu\text{m}$ . The pharmaceutical composition can be formulated into a wide variety of dosage forms for treatment of seizures.

=> d his

(FILE 'HOME' ENTERED AT 13:03:43 ON 29 NOV 2007)

FILE 'REGISTRY' ENTERED AT 13:03:52 ON 29 NOV 2007

L1 1 S 84057-84-1/RN

FILE 'HCAPLUS' ENTERED AT 13:04:14 ON 29 NOV 2007

L2 1461 S L1

L3 278076 S PARTICLE (A) SIZE

L4 35036 S SPECIFIC (A) SURFACE (A) AREA

L5 5893 S L3 AND L4

L6 0 S L5 AND L2

L7 1 S L4 AND L2

L8 12 S L2 AND L3

FILE 'STNGUIDE' ENTERED AT 13:06:40 ON 29 NOV 2007

L9 0 S PARTICLE (A) DIAMETER

L10 0 S L1 AND PARTICLE?

FILE 'HCAPLUS' ENTERED AT 13:12:23 ON 29 NOV 2007

L11 36158 S PARTICLE (A) DIAMETER

L12 2 S L11 AND L1

=> s l1 and particl??

'?' TRUNCATION SYMBOL NOT VALID WITHIN 'PARTICL??'

The truncation symbol ? may be used only at the end of a search term. To specify a variable character within a word use '!', e.g., 'wom!n' to search for both 'woman' and 'women'. Enter "HELP TRUNCATION" at an arrow prompt (=>) for more information.

=> s l1 and particle?

1461 L1

1293555 PARTICLE?

L13 22 L1 AND PARTICLE?

=> d l13 1-22 ibib abs

L13 ANSWER 1 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:874559 HCAPLUS

DOCUMENT NUMBER: 147:220128

TITLE: Drug delivery systems comprising weakly basic drugs and organic acids

INVENTOR(S): Venkatesh, Gopi M.

PATENT ASSIGNEE(S): Eurand, Inc., USA

SOURCE: PCT Int. Appl., 58pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007090091	A2	20070809	WO 2007-US61237	20070129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 2007196491 A1 20070823 US 2007-668408 20070129 US 2006-762766P P 20060127				

PRIORITY APPLN. INFO.:

AB A pharmaceutical dosage form such as a capsule, a conventional or orally disintegrating tablet capable of delivering a nitrogen (N)-containing therapeutic agent having a pKa in the range of from about 5 to 14 into the body in a sustained-released fashion, in order to be suitable for a twice- or once-daily dosing regimen, comprises at least one organic acid, which solubilizes the therapeutic agent the drug prior to releasing it into the hostile intestinal environment wherein said weakly basic drug is practically insol. The unit dosage form is composed of a multitude of multicoated particulates (i.e., immediate-release beads, sustained-release beads and/or one or more timed, pulsatile-release bead populations) is designed in such a way that said weakly basic drug and said organic acid do not come into close contact during processing and/or storage for in-situ formation of acid addition compds. while ensuring that the acid is not depleted prior to completion of the drug release. Dipyrimadole immediate-release beads (obtained by coating sustained-release coated fumaric acid cores) were barrier-coated by spraying a solution of 90/10 EC-10/TEC (tri-Et citrate) at 5-10% by weight and dried in the Glatt for 10 min to obtain sustained-release beads.

L13 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:817115 HCAPLUS

DOCUMENT NUMBER: 147:197361

TITLE: Multi-parameter monitoring device for use with central and intravenous administration of medication

INVENTOR(S): Abrams, Daniel J.; Bunch, Raymond; Royals, Michael

PATENT ASSIGNEE(S): Regents of the University of Colorado, USA

SOURCE: PCT Int. Appl., 38pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007084777	A2	20070726	WO 2007-US1692	20070122
WO 2007084777	A9	20071004		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:

US 2006-760813P

P 20060120

AB The invention discloses a multi-parameter monitoring device for in-line use to monitor a therapeutic agent solution passing therethrough prior to being centrally administered in connection with treatment of a CNS-related condition or disorder, e.g., a neuropsychiatric disorder. In another aspect, the invention relates to a multi-parameter monitoring device for in-line use to monitor a therapeutic agent solution passing therethrough prior to being (a) i.v. administered to a patient in connection with a treatment, such as is the case where the therapeutic agent solution comprises an IV administerable solution, or (b) administered to a patient in connection with a treatment for diabetes, such as is the case where the therapeutic agent comprises insulin.

L13 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:728812 HCAPLUS

DOCUMENT NUMBER: 147:125588

TITLE: Mouth dissolving pharmaceutical composition and process for preparing the same

INVENTOR(S): Kashid, Namdev; Mukherji, Gour

PATENT ASSIGNEE(S): Jubilant Organosys Limited, India

SOURCE: PCT Int. Appl., 25pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007074472	A2	20070705	WO 2006-IN319	20060830
WO 2007074472	A3	20070816		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:

IN 2005-DE3482

A 20051227

AB Disclosed herein is an orally disintegrating and/or dissolving oral

pharmaceutical composition, comprising one or more active pharmaceutical ingredients, one or more fillers having particle size of 100  $\mu$  or above, a high and desirable amount of SiO<sub>2</sub>, one or more disintegrating agents, optionally effervescent couple, wherein said composition has good organoleptic properties like desired mouth feel and fast oral disintegration time.

L13 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:475563 HCAPLUS

DOCUMENT NUMBER: 146:474685

TITLE: Isocratic reversed-phase HPLC for simultaneous separation and determination of seven antiepileptic drugs and two of their active metabolites in human plasma

AUTHOR(S): Ma, Chun-Lai; Jiao, Zheng; Jie, Yang; Shi, Xiao-Jin

CORPORATE SOURCE: Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, Peop. Rep. China

SOURCE: Chromatographia (2007), 65(5/6), 267-275

CODEN: CHRGB7; ISSN: 0009-5893

PUBLISHER: Vieweg Verlag/GWV Fachverlage GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A simple reversed-phase HPLC method was developed for the simultaneous determination of the antiepileptic drugs (AEDs) zonisamide (ZNS), primidone (PRI),

Lamotrigine (LTG), phenobarbital (PB), phenytoin (PHT), oxcarbazepine (OXC), and carbamazepine (CBZ) and 2 of their active metabolites, monohydroxycarbamazepine (MHD) and carbamazepine 10,11-epoxide (CBZE), in human plasma. Plasma (100  $\mu$ L) was pretreated by deproteinization with 300  $\mu$ L methanol containing 20  $\mu$ g mL<sup>-1</sup> propranolol hydrochloride as internal standard. HPLC was performed on a C8 column (4.6 mm  $\times$  250 mm; particle size 5  $\mu$ m) with methanol-acetonitrile-0.1% trifluoroacetic acid, 235:120:645 (volume/volume), as mobile phase at a flow rate of 1.5 mL min<sup>-1</sup>. ZNS, OXC, and CBZ were monitored by UV detection at 235 nm, and PRI, LTG, MHD, PB, PHT, and CBZE by UV detection at 215 nm. Relationships between response and concentration were linear over the concentration

ranges 1-80  $\mu$ g mL<sup>-1</sup> for ZNS, 5-50  $\mu$ g mL<sup>-1</sup> for PRI, 1-25  $\mu$ g mL<sup>-1</sup> for LTG, 1-50  $\mu$ g mL<sup>-1</sup> for MHD, 5-100  $\mu$ g mL<sup>-1</sup> for PB, 1-10  $\mu$ g mL<sup>-1</sup> for CBZE, 0.5-25  $\mu$ g mL<sup>-1</sup> for OXC, 1-50  $\mu$ g mL<sup>-1</sup> for PHT, and 1-25  $\mu$ g mL<sup>-1</sup> for CBZ. Intra- and interday reproducibility were adequate (coeffs. of variation were  $\leq$ 11.6%) and absolute recovery ranged from 95.2  $\pm$  6.13 to 107.7  $\pm$  7.76% for all the analytes; for the IS, recovery was 98.69  $\pm$  1.12%. The method was accurate, reproducible, convenient, and suitable for therapeutic monitoring of the 9 analytes.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:385013 HCAPLUS

DOCUMENT NUMBER: 146:387123

TITLE: Microparticles with modified release of at least one active principle and oral galenic form comprising same

INVENTOR(S): Dargelas, Frederic; Guimberteau, Florence; Castan, Catherine; Meyrueix, Remi; Soula, Gerard

PATENT ASSIGNEE(S): Flamel Technologies, Fr.

SOURCE: PCT Int. Appl., 50pp.

CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007036671	A2	20070405	WO 2006-FR50944	20060927
WO 2007036671	A3	20070524		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
FR 2891459	A1	20070406	FR 2005-52985	20050930

## PRIORITY APPLN. INFO.:

FR 2005-52985 A 20050930

AB The invention concerns microparticle systems with modified release of oral active principle(s). The invention aims at providing a novel multimicroparticle galenic system operating in accordance with a dual time-dependent and pH-dependent release mechanism, which enables the following three parameters to be adjusted independently of one another: (a) the latent period preceding the release of the active principle in the stomach; (b) the pH triggering the release of the active principle in the intestine; (c) the release speed of the active principle. This is achieved through the use of coated microparticles made from particles of active principle each coated with two coating films A and B. Film A comprises: film-forming (co)polymer (A1) insol. in fluids of the gastrointestinal tract, Et cellulose (co)polymer (A2) soluble in fluids of the gastrointestinal tract, plasticizing polyvinylpyrrolidone (A3), and castor oil and optionally a surfactant and/or magnesium stearate lubricant (A4). Film B comprises a hydrophilic polymer (B1) bearing ionized groups with neutral pH (Eudragit L100-55) and a hydrophobic compound (B2) (Lubritab). Metformin hydrochloride and povidone were dissolved in water and spray-dried over neural microspheres. The microspheres were then coated to obtain prolonged-release metformin microparticles.

L13 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:411970 HCAPLUS

DOCUMENT NUMBER: 144:425648

TITLE: Lamotrigine analogs for production of anti-lamotrigine antibodies and use as immunoassay reagents

INVENTOR(S): Ouyang, Anlong; Arabshahi, Lili; Roberts, Mark; Wall, Melissa

PATENT ASSIGNEE(S): Seradyn, Inc., USA

SOURCE: PCT Int. Appl., 131 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006047372	A2	20060504	WO 2005-US38100	20051021
WO 2006047372	A3	20060727		
WO 2006047372	A9	20061005		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006115865	A1	20060601	US-2005-254650-1	20051020
CA 2586474	A1	20060504	CA 2005-2586474	20051021
EP 1809615	A2	20070725	EP 2005-823387	20051021
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRIORITY APPLN. INFO.:			US 2004-621764P	P 20041025
			US 2005-254650	A 20051020
			WO 2005-US38100	W 20051021

OTHER SOURCE(S): MARPAT 144:425648

AB The invention discloses lamotrigine analogs that have substituents at the triazine 3-position and on the benzene 4-position and 5-position. The lamotrigine analogs can include immunogenic moieties that can be used to prepare anti-lamotrigine antibodies, or antigenic moieties that can be used in immunodiagnostic assays for lamotrigine. Also, the lamotrigine analog can include tracer moieties for detecting the presence or amount of the analog during an immunodiagnostic assay. Addnl., the lamotrigine analogs can be used in immunodiagnostic assays to compete with lamotrigine for binding with anti-lamotrigine antibodies. Lamotrigine analog preparation is described.

L13 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:142759 HCAPLUS

DOCUMENT NUMBER: 144:239925

TITLE: Solid carriers for improved delivery of active ingredients containing surfactants and glycerides

INVENTOR(S): Patel, Mahesh

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U.S. Ser. No. 428,341.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2006034937	A1	20060216	US 2005-196805	20050802
US 6248363	B1	20010619	US 1999-447690	19991123
US 2003064097	A1	20030403	US 2001-800593	20010306
US 6569463	B2	20030527		
US 2003215496	A1	20031120	US 2003-428341	20030501
US 6923988	B2	20050802		
WO 2007018943	A2	20070215	WO 2006-US27159	20060712

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

## PRIORITY APPLN. INFO.:

US 1999-447690	A3	19991123
US 2001-800593	A1	20010306
US 2003-428341	A2	20030501
US 2005-196805	A	20050802

AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compns. of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents. For example, particles contained glyburide, PEG stearate, glycerol monolaurate, and Nonpareil seed.

L13 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1241184 HCAPLUS

DOCUMENT NUMBER: 143:483161

TITLE: Mouth dissolvable and meltable, and water dispersable delivery formulation for antiepileptics

INVENTOR(S): Chakravorty, Saibal; Hariharan, V.

PATENT ASSIGNEE(S): Rpg Life Sciences Limited, India

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005109990	A2	20051124	WO 2005-IN101	20050404
WO 2005109990	A3	20060706		



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IN 2004MU00419 A 20060303 IN 2004-MU419 20040406  
 AU 2005244329 A1 20051124 AU 2005-244329 20050404  
 CA 2562213 A1 20051124 CA 2005-2562213 20050404  
 EP 1737405 A2 20070103 EP 2005-768079 20050404

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

IN 2005MU00426 A 20070525 IN 2005-MU426 20050404  
 PRIORITY APPLN. INFO.: IN 2004-MU419 A 20040406  
 WO 2005-IN101 W 20050404

AB A mouth dissolvable and meltable, and water dispersible delivery system for oral administration consisting of an antiepileptic drug, one or more swelling agents, one or more of fillers, one or more of disintegrating agents, and one or more of binders is disclosed. The swelling agent is powdered cellulose, filler is spray dried mannitol, disintegrating agent is crosslinked polyvinyl pyrrolidone and binder is maltodextrin. This system optionally comprises one or more of other excipients selected from the group comprising lubricants, sweeteners and flavoring agent.

L13 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:493490 HCAPLUS  
 DOCUMENT NUMBER: 143:32332  
 TITLE: Water dispersible tablet  
 INVENTOR(S): Gupta, Vinod Kumar; Vaya, Navin; Sougata, Pramanick  
 PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India  
 SOURCE: PCT Int. Appl., 33 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051350	A2	20050609	WO 2004-IN312	20041007
WO 2005051350	A3	20050818		
WO 2005051350	B1	20050929		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

IN 2003MU01128 A 20070504 IN 2003-MU1128 20031028  
PRIORITY APPLN. INFO.: IN 2003-MU1128 A 20031028

AB This invention relates to a water-dispersible formulation of an active pharmaceutical ingredient or pharmaceutically acceptable salt hereof and one or more adjuvants without the use of swellable clay. More particularly, the invention comprises a dispersible formulation of anti-epileptic drug - lamotrigine. This invention further relates to a process for the preparation of said formulation.

L13 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:366596 HCAPLUS

DOCUMENT NUMBER: 143:65658

TITLE: Optimisation and use of water-in-oil MEEKC in pharmaceutical analysis

AUTHOR(S): Broderick, Margo; Donegan, Sheila; Power, Joe; Altria, Kevin

CORPORATE SOURCE: Waterford Institute of Technology, Department of Chemical and Life Sciences, Waterford, Ire.

SOURCE: Journal of Pharmaceutical and Biomedical Analysis (2005), 37(5), 877-884

CODEN: JPBADA; ISSN: 0731-7085

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Water-in-oil microemulsion electrokinetic chromatog. was applied to the separation of a range of acids, bases and neutrals and is especially suitable for very water-insol. drug compds. A number of operating parameters were evaluated. An optimized set of operating conditions allowed separation of a range of pharmaceutical formulations containing water-insol. compds.. A number of novel applications for W/O microemulsions were developed and ability to quantify drug contents in tablets and a cream was shown with good precision, detector linearity and accuracy. Comparison of obtained data with those determined from a HPLC method showed acceptable agreement.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:325504 HCAPLUS

DOCUMENT NUMBER: 142:379390

TITLE: Pharmaceutical formulations comprising microparticles with improved dispersibility, suspendability or wettability

INVENTOR(S): Chickering, Donald E.; Reese, Shaina; Narasimhan, Sridhar; Straub, Julie A.; Bernstein, Howard; Altreuter, David; Huang, Eric K.; Brito, Luis A.; Jain, Rajeev A.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 324,550.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005079138	A1	20050414	US 2004-955261	20040930
US 2004121003	A1	20040624	US 2002-324558	20021219
PRIORITY APPLN. INFO.:			US 2002-324558	A2 20021219

AB Methods are provided for making a dry powder blend pharmaceutical formulation, comprising the steps of: (a) providing microparticles which comprise a pharmaceutical agent; (b) blending the microparticles with at least one excipient in the form of particles to form a powder blend; and (c) jet milling the powder blend to form a dry powder blend pharmaceutical formulation having improved dispersibility, suspendability, or wettability as compared to the microparticles of step (a) or the powder blend of step (b). The method can further include dispersing the dry powder blend pharmaceutical formulation in a liquid pharmaceutically acceptable vehicle to make an formulation suitable for injection. Alternatively, the method can further include processing the dry powder blend pharmaceutical formulation into a solid oral dosage form. In one embodiment, the microparticles of step (a) are formed by a solvent

precipitation

or crystallization process. PLGA microspheres containing mannitol and Tween 80 having

number average particle size of 1.96  $\mu$ m, and volume average particle size of 4.04  $\mu$ m were prepared. The jet milling provided significant particle deagglomeration.

L13 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:216629 HCAPLUS

DOCUMENT NUMBER: 142:285200

TITLE: Nanoparticles for drug delivery

INVENTOR(S): Turos, Edward; Shim, Jeung-Yeop

PATENT ASSIGNEE(S): University of South Florida, USA

SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020933	A2	20050310	WO 2004-US28995	20040902
WO 2005020933	A3	20050609		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2007190160	A1	20070816	US 2006-570461	20060302

## PRIORITY APPLN. INFO.:

US 2003-499904P P 20030902  
 US 2003-500750P P 20030904  
 US 2004-568746P P 20040506  
 WO 2004-US28995 W 20040902

AB This invention relates to a unique process for the preparation of polymeric nanoparticles with target mols. bonded to the surface of the particles and having sizes of up to 1000 nm, preferably 1-400 nm, more preferably 1-200 nm, that are dispersed homogeneously in aqueous solution. To accomplish the above objective, the polymeric nanoparticles of the subject invention are prepared using a novel technique of microemulsion polymerization. The resulting aqueous solution of polymeric nanoparticles is comprised of about 1-100 parts per weight of water or buffer, about 1-80 parts per weight of polymeric nanoparticles, which the bioactive mols. are conjugated, about 0.001-10 parts per weight of emulsifier, and about 0.00001-5 parts per weight of radical initiator based on the weight of the solution. In the method of this invention, the target drug/target substance is covalently bonded to the polymeric nanoparticles to secure them from outer intervention in vivo or cell culture in vitro until they are exposed at the target site within the cell. Nanoparticles of ethylacrylate-N-methylthiolated 3-lactam copolymer were prepared by a radical polymerization using potassium persulfate as the initiator and the sodium salt of dodecyl sulfate as the surfactant. The particle size was 40-80 nm. The antibacterial activity of the nanoparticles is shown.

L13 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1036887 HCAPLUS

DOCUMENT NUMBER: 142:11520

TITLE: Breakable, controlled-release tablets comprising a preformed passage

INVENTOR(S): Faour, Joaquina; Vergez, Juan A.

PATENT ASSIGNEE(S): Osmotica Costa Rica, Sociedad Anonima, Costa Rica

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Spanish

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103349	A2	20041202	WO 2004-CR5	20040521
WO 2004103349	A3	20050331		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2526464	A1	20041202	CA 2004-2526464	20040521

EP 1629835 A2 20060301 EP 2004-738451 20040521  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK  
 BR 2004010546 A 20060620 BR 2004-10546 20040521  
 PRIORITY APPLN. INFO.: US 2003-472819P P 20030522  
 WO 2004-CR5 W 20040521

AB The invention relates to a simple and improved osmotic device for the controlled release of an active agent from the core into the use environment. According to the invention, the active agent is first released through a preformed passage and, subsequently, through a second passage which is formed in situ. Optionally, the size of one or both of the passages increases during the use of the osmotic device. Moreover, the preformed passage and/or the second passage increases the release speed of the active agent and enables the release of larger particles containing the active agent and/or the release of active agents which are essentially insol. in the use environment. Owing to the in situ formation of the second opening, the device can release a greater percentage of active agent than that which would be released without said second opening.

L13 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:430288 HCAPLUS

DOCUMENT NUMBER: 140:429017

TITLE: Drug condensation aerosols and kits

INVENTOR(S): Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Lu, Amy T.; Myers, Daniel J.; Rabinowitz, Joshua D.; Wensley, Martin J.

PATENT ASSIGNEE(S): Alexza Molecular Delivery Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 84 pp., Cont.-in-part of U.S. Ser. No. 633,877.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 34

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004099269	A1	20040527	US 2003-718982	20031120
US 7090830	B2	20060815		
US 2003051728	A1	20030320	US 2001-57198	20011026
US 2003015197	A1	20030123	US 2002-146088	20020513
US 2003017115	A1	20030123	US 2002-146516	20020513
US 6737042	B2	20040518		
US 2003035776	A1	20030220	US 2002-146515	20020513
US 6682716	B2	20040127		
US 2003209240	A1	20031113	US 2002-146086	20020513
CN 1990057	A	20070704	CN 2007-10002060	20020513
US 2003007933	A1	20030109	US 2002-150267	20020515
US 6797259	B2	20040928		
US 2003007934	A1	20030109	US 2002-150268	20020515
US 6780399	B2	20040824		
US 2003091511	A1	20030515	US 2002-150056	20020515
US 6805853	B2	20041019		
AU 2002309948	A1	20030526	AU 2002-309948	20020515
US 2003017117	A1	20030123	US 2002-151596	20020516
US 6855310	B2	20050215		

US 2003206869	A1	20031106	US 2002-151626	20020516
US 6783753	B2	20040831		
US 2003017116	A1	20030123	US 2002-150857	20020517
US 6716415	B2	20040406		
US 2003021753	A1	20030130	US 2002-150591	20020517
US 6780400	B2	20040824		
US 2003005924	A1	20030109	US 2002-152652	20020520
US 6740307	B2	20040525		
US 2003012740	A1	20030116	US 2002-153139	20020520
US 6814954	B2	20041109		
US 2003017118	A1	20030123	US 2002-152639	20020520
US 6716416	B2	20040406		
US 2003021754	A1	20030130	US 2002-152640	20020520
US 6743415	B2	20040601		
US 2003012737	A1	20030116	US 2002-153311	20020521
US 6884408	B2	20050426		
US 2003015189	A1	20030123	US 2002-153831	20020521
US 6740308	B2	20040525		
US 2003017119	A1	20030123	US 2002-153839	20020521
US 6776978	B2	20040817		
US 2003032638	A1	20030213	US 2002-153313	20020521
US 2003005925	A1	20030109	US 2002-155621	20020522
US 6759029	B2	20040706		
US 2003012738	A1	20030116	US 2002-155373	20020522
US 6737043	B2	20040518		
US 2003017120	A1	20030123	US 2002-155703	20020522
US 6803031	B2	20041012		
US 2003021755	A1	20030130	US 2002-155705	20020522
US 6805854	B2	20041019		
US 2003000518	A1	20030102	US 2002-155097	20020523
US 6716417	B2	20040406		
US 2003015190	A1	20030123	US 2002-154594	20020523
US 6740309	B2	20040525		
US 2003017114	A1	20030123	US 2002-154765	20020523
US 6814955	B2	20041109		
US 2003118512	A1	20030626	US 2002-280315	20021025
WO 2003045484	A2	20030605	WO 2002-US37491	20021121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002364508	A1	20030610	AU 2002-364508	20021121
US 2003138382	A1	20030724	US 2002-302010	20021121
US 7078016	B2	20060718		
US 2003138508	A1	20030724	US 2002-322227	20021217
US 2007031340	A1	20070208	US 2003-633877	20030804
US 2004126326	A1	20040701	US 2003-734902	20031212
US 7029658	B2	20060418		
US 2004127481	A1	20040701	US 2003-735198	20031212
US 7008615	B2	20060307		
US 2004126327	A1	20040701	US 2003-735199	20031212

US 7070761	B2	20060704		
US 2004127490	A1	20040701	US 2003-735495	20031212
US 7018619	B2	20060328		
US 2004126329	A1	20040701	US 2003-735497	20031212
US 7070762	B2	20060704		
US 2004156788	A1	20040812	US 2003-749535	20031230
US 7115250	B2	20061003		
US 2004156789	A1	20040812	US 2003-749536	20031230
US 7094392	B2	20060822		
US 2004156790	A1	20040812	US 2003-749783	20031230
US 7078019	B2	20060718		
US 2004156791	A1	20040812	US 2003-750303	20031230
US 7078020	B2	20060718		
US 2005075273	A1	20050407	US 2003-749539	20031230
US 7078018	B2	20060718		
US 2005089479	A1	20050428	US 2003-749537	20031230
US 7078017	B2	20060718		
US 2004184996	A1	20040923	US 2004-766279	20040127
US 7087217	B2	20060808		
US 2004191179	A1	20040930	US 2004-766566	20040127
US 7060254	B2	20060613		
US 2004191181	A1	20040930	US 2004-766634	20040127
US 7070763	B2	20060704		
US 2004191182	A1	20040930	US 2004-766647	20040127
US 7070764	B2	20060704		
US 2004228807	A1	20041118	US 2004-766149	20040127
US 7087216	B2	20060808		
US 2004184997	A1	20040923	US 2004-767115	20040128
US 7052679	B2	20060530		
US 2004184998	A1	20040923	US 2004-768205	20040129
US 7070765	B2	20060704		
US 2004184999	A1	20040923	US 2004-768220	20040129
US 7063830	B2	20060620		
US 2004185000	A1	20040923	US 2004-768293	20040129
US 7067114	B2	20060627		
US 2004185003	A1	20040923	US 2004-769157	20040129
US 7060255	B2	20060613		
US 2004185004	A1	20040923	US 2004-769197	20040129
US 7063831	B2	20060620		
US 2004202617	A1	20041014	US 2004-768281	20040129
US 7169378	B2	20070130		
US 2004185001	A1	20040923	US 2004-769046	20040130
US 7070766	B2	20060704		
US 2004185002	A1	20040923	US 2004-769051	20040130
US 7033575	B2	20060425		
US 2004161385	A1	20040819	US 2004-775586	20040209
US 7048909	B2	20060523		
US 2004167228	A1	20040826	US 2004-775583	20040209
US 7018620	B2	20060328		
US 2004185005	A1	20040923	US 2004-813721	20040331
US 7022312	B2	20060404		
US 2004186130	A1	20040923	US 2004-813722	20040331
US 7063832	B2	20060620		
US 2004191183	A1	20040930	US 2004-814690	20040331
US 7014841	B2	20060321		
US 2004191184	A1	20040930	US 2004-814998	20040331
US 7108847	B2	20060919		

US 2004185006	A1	20040923	US 2004-815527	20040401
US 6994843	B2	20060207		
US 2004185007	A1	20040923	US 2004-816407	20040401
US 7011820	B2	20060314		
US 2004185008	A1	20040923	US 2004-816567	20040401
US 7052680	B2	20060530		
US 2004191185	A1	20040930	US 2004-816492	20040401
US 7008616	B2	20060307		
US 2006153779	A1	20060713	US 2006-370628	20060307
US 2006177382	A1	20060810	US 2006-398383	20060404
US 2006216243	A1	20060928	US 2006-439475	20060524
US 2006216244	A1	20060928	US 2006-442917	20060530
US 2006233718	A1	20061019	US 2006-451852	20060613
US 2006233719	A1	20061019	US 2006-451853	20060613
US 2006239936	A1	20061026	US 2006-454573	20060616
US 2006246011	A1	20061102	US 2006-479361	20060630
US 2006246012	A1	20061102	US 2006-479509	20060630
US 2006251587	A1	20061109	US 2006-479892	20060630
US 2006251588	A1	20061109	US 2006-481279	20060705
US 2006257328	A1	20061116	US 2006-488302	20060718
US 2006257329	A1	20061116	US 2006-488943	20060718
US 2006280692	A1	20061214	US 2006-488932	20060718
US 2006269487	A1	20061130	US 2006-501246	20060807
US 2006286042	A1	20061221	US 2006-500735	20060807
US 2007122353	A1	20070531	US 2006-504419	20060815
US 2006286043	A1	20061221	US 2006-507986	20060822
US 2007014737	A1	20070118	US 2006-523685	20060919
US 2007178052	A1	20070802	US 2007-621397	20070109
AU 2007207865	A1	20070906	AU 2007-207865	20070816
PRIORITY APPLN. INFO.:			US 2001-57197	A2 20011026
			US 2001-57198	A2 20011026
			US 2001-345882P	P 20011109
			US 2001-332165P	P 20011121
			US 2001-332279P	P 20011121
			US 2001-332280P	P 20011121
			US 2001-342066P	P 20011218
			US 2002-50056	B2 20020114
			US 2002-57098	A2 20020123
			US 2002-371457P	P 20020409
			US 2002-146080	A2 20020513
			US 2002-146086	A2 20020513
			US 2002-146088	A2 20020513
			US 2002-146515	A2 20020513
			US 2002-146516	A2 20020513
			US 2002-150056	A2 20020515
			US 2002-150267	A2 20020515
			US 2002-150268	A2 20020515
			US 2002-151596	A2 20020516
			US 2002-151626	A2 20020516
			US 2002-150591	A2 20020517
			US 2002-150857	A2 20020517
			US 2002-152639	A2 20020520
			US 2002-152640	A2 20020520
			US 2002-152652	A2 20020520
			US 2002-153139	A2 20020520
			US 2002-153311	A2 20020521
			US 2002-153313	B2 20020521



US 2002-153831	A2 20020521
US 2002-153839	A2 20020521
US 2002-155373	A2 20020522
US 2002-155621	A2 20020522
US 2002-155703	A2 20020522
US 2002-155705	A2 20020522
US 2002-154594	A2 20020523
US 2002-154765	A2 20020523
US 2002-155097	A2 20020523
US 2002-412068P	P 20020918
US 2002-280315	A2 20021025
US 2002-302010	A2 20021121
US 2002-302614	A2 20021121
US 2002-322227	A2 20021217
US 2003-633876	A2 20030804
US 2003-633877	A2 20030804
US 2001-294203P	P 20010524
US 2001-296225P	P 20010605
US 2001-317479P	P 20010905
US 2001-335049P	P 20011030
US 2001-336218P	P 20011030
US 2001-345145P	P 20011109
US 2001-345876P	P 20011109
AU 2002-311923	A3 20020513
CN 2002-811406	A3 20020513
WO 2002-US15820	W 20020515
WO 2002-US37491	W 20021121
US 2003-718982	A1 20031120
US 2003-734902	A1 20031212
US 2003-735198	A1 20031212
US 2003-735199	A1 20031212
US 2003-735495	A1 20031212
US 2003-735497	A1 20031212
US 2003-749535	A1 20031230
US 2003-749536	A1 20031230
US 2003-749537	A1 20031230
US 2003-749539	A1 20031230
US 2003-749783	A1 20031230
US 2003-750303	A1 20031230
US 2004-766149	A1 20040127
US 2004-766279	A1 20040127
US 2004-766566	A1 20040127
US 2004-766634	A1 20040127
US 2004-766647	A1 20040127
US 2004-768220	A1 20040129
US 2004-768281	A1 20040129
US 2004-769157	A1 20040129
US 2004-769046	A1 20040130
US 2004-775586	A1 20040209
US 2004-813721	A1 20040331
US 2004-814998	A1 20040331
US 2004-816492	A1 20040401
US 2004-816567	A1 20040401

AB The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3  $\mu$ . The aerosols are

made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20  $\mu\text{m}$ , while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically ED of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits. For example, acebutolol (MW 336, m.p. 123°, oral dose 400 mg), a  $\beta$ -adrenergic blocker (cardiovascular agent), was coated on a stainless steel cylinder (8 cm). The drug (0.89 mg) was applied to the substrate, for a calculated drug film thickness of 1.1  $\mu\text{m}$ . The substrate was heated at 20.5 V and purity of the drug aerosol particles was determined to be 98.9%; 0.53 mg was recovered from the filter after vaporization, for a percent yield of 59.6%. A total mass of 0.81 mg was recovered from the test apparatus and substrate, for a total recovery of 91%. High speed photographs were taken as the drug-coated substrate was heated to monitor visually formation of a thermal vapor. The photographs showed that a thermal vapor was initially visible 30 ms after heating was initiated, with the majority of the thermal vapor formed by 130 ms. Generation of the thermal vapor was complete by 500 ms.

L13 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:991477 HCAPLUS  
 DOCUMENT NUMBER: 140:31517  
 TITLE: Controlled release formulation of lamotrigine  
 INVENTOR(S): Nadkarni, Sunil Sadanand  
 PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India  
 SOURCE: PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104192	A2	20031218	WO 2003-IN213	20030606
WO 2003104192	A3	20040311		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004043996	A1	20040304	US 2003-452772	20030602
CA 2488868	A1	20031218	CA 2003-2488868	20030606
AU 2003267808	A1	20031222	AU 2003-267808	20030606
BR 2003011701	A	20050308	BR 2003-11701	20030606
EP 1513535	A2	20050316	EP 2003-748504	20030606
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

IN 2004MN00051 A 20050624 IN 2004-MN51 20040120  
 IN 2004MN00393 A 20050429 IN 2004-MN393 20040719  
 PRIORITY APPLN. INFO.: US 2002-386795P P 20020607  
 WO 2003-IN213 W 20030606  
 IN 2004-MN51 A3 20040120

AB Rapidly disintegrating multiparticulate controlled-release formulations of lamotrigine having an improved pharmacokinetic profile and improved patient compliance, and process of preparing the formulations are described. The formulations comprise pelleted cores covered with one or more different rate-controlling polymeric membrane(s). It provides better control of blood plasma levels than conventional tablet formulations that is administered once or more times a day. For example, granules (core particles, diameter of 0.15 to 0.30 mm) were prepared using a fluidized bed processor from 750 g of microcryst. cellulose and a bulk liquid containing lamotrigine 900.00 g, hydroxypropyl Me cellulose 545.45 g, and water 13.20 kg. The 1500 g of the drug granules (core particles) were spray coated with a rate-controlling coating membrane composition containing

## Eudragit RS

PO 163.84 g, Eudragit RL PO 8.617 g, tri-Et citrate 34.5 g, talc 55.52 g, methylene chloride 997.5 g, and iso-Pr alc. 1671.25 g to obtain controlled-release particles. The controlled-release particles prepared were filled into capsules (50 mg/capsule) and showed better pharmacokinetic profile than the conventional tablets.

L13 ANSWER 16 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:971868 HCAPLUS

DOCUMENT NUMBER: 140:19871

TITLE: Delayed release drug delivery systems containing polymers and method for preparation by mixing and compacting

INVENTOR(S): Hanshermann, Franke; Lennartz, Peter; Raimier, Joern

PATENT ASSIGNEE(S): Desitin Arzneimittel GmbH, Germany

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101428	A1	20031211	WO 2003-EP5115	20030515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10224170	A1	20031211	DE 2002-10224170	20020531
CA 2485080	A1	20031211	CA 2003-2485080	20030515
AU 2003236658	A1	20031219	AU 2003-236658	20030515
BR 2003011512	A	20050222	BR 2003-11512	20030515
EP 1509205	A1	20050302	EP 2003-735396	20030515

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005528428	T	20050922	JP 2004-508786	20030515
DE 20321237	U1	20060727	DE 2003-20321237	20030515
DE 20321314	U1	20061116	DE 2003-20321314	20030515
MX 2004PA11813	A	20050726	MX 2004-PA11813	20041126
NO 2004005386	A	20041209	NO 2004-5386	20041209
US 2005202088	A1	20050915	US 2005-516268	20050527
PRIORITY APPLN. INFO.:			DE 2002-10224170	A 20020531
			DE 2002-10224177	IA 20020531
			DE 2002-10250566	IA 20021030
			EP 2003-730048	A 20030515
			EP 2003-735396	A 20030515
			WO 2003-EP5115	W 20030515

AB The invention relates to a pharmaceutical composition, which has a delayed active substance release and can be obtained by means of a special compacting method for which organic solvents and water are not required. Said pharmaceutical composition preferably exists in the form of individual active substance compartments or breaks down into compartments of this type when brought into contact with aqueous media. Various types of drugs can be formulated with acrylic copolymers. Thus 30 kg of oxcarbazepine and 9 kg of Eudragit RSPO were mixed in a quick mixer (Diosna P 100); the mixture was compacted using a Gerteis 3 W-Polygran roller compactor applying 15-40 kN/cm at 80°C. The product was disintegrated by forced sieving and classified through a mash. The particles were encapsulated in hard gel capsules.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 17 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:875073 HCAPLUS

DOCUMENT NUMBER: 139:354488

TITLE: Pharmaceutical composition containing lamotrigine particles of defined morphology

INVENTOR(S): Aronhime, Judith; Samburski, Guy

PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003090693	A2	20031106	WO 2003-US13002	20030423
WO 2003090693	A3	20040108		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,			

	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2483103	A1 20031106 CA 2003-2483103 20030423
AU 2003234240	A1 20031110 AU 2003-234240 20030423
EP 1496864	A2 20050119 EP 2003-728552 20030423
EP 1496864	B1 20070321

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,	
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
AT 357217	T 20070415 AT 2003-728552 20030423
ES 2282628	T3 20071016 ES 2003-3728552 20030423
US 2005238724	A1 20051027 US 2004-511987 20041021

## PRIORITY APPLN. INFO.:

US 2002-374923P	P 20020423
WO 2003-US13002	W 20030423

AB The present invention provides a pharmaceutical composition comprising a plurality of lamotrigine particles having a sp. surface area of from about two to about three and a half meters per g. Pharmaceutical compns. falling within the surface area criteria for the lamotrigine particles include those having a particle diameter equal to or less than about 100  $\mu\text{m}$ , preferably about 50  $\mu\text{m}$ , and most preferably 10  $\mu\text{m}$ . The pharmaceutical composition can be formulated into a wide variety of dosage forms for treatment of seizures.

L13 ANSWER 18 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:726750 HCAPLUS

DOCUMENT NUMBER: 139:333072

TITLE: Identification and prediction of promiscuous aggregating inhibitors among known drugs

AUTHOR(S): Seidler, James; McGovern, Susan L.; Doman, Thompson N.; Shoichet, Brian K.

CORPORATE SOURCE: Department of Molecular Pharmacology and Biological Chemistry, Northwestern University, Chicago, IL, 60611, USA

SOURCE: Journal of Medicinal Chemistry (2003), 46(21), 4477-4486

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Some small mols., often hits from screening, form aggregates in solution that inhibit many enzymes. In contrast, drugs are thought to act specifically. To investigate this assumption, 50 unrelated drugs were tested for promiscuous inhibition via aggregation. Each drug was tested against three unrelated model enzymes:  $\beta$ -lactamase, chymotrypsin, and malate dehydrogenase, none of which are considered targets of these drugs. To be judged promiscuous, the drugs had to inhibit all three enzymes, do so in a time-dependent manner, be sensitive to detergent and to enzyme concentration, and

form particles detectable by light scattering. Of the 50 drugs tested, 43 were nonpromiscuous by these criteria. Surprisingly, four of the drugs showed promiscuous, aggregation-based inhibition at concns. below 100  $\mu\text{M}$ : clotrimazole, benzyl benzoate, nifedipine, and delavirdine. Three other drugs also behaved as aggregation-based inhibitors, but only at high concns. (about 400  $\mu\text{M}$ ). To investigate possible structure-activity relationships among promiscuous drugs, five analogs of the antifungal clotrimazole were studied. Three of these, miconazole, econazole, and sulconazole, were promiscuous but the other two, fluconazole and ketoconazole, were not. Using recursive partitioning, these exptl. results were used to develop a model for

predicting aggregate-based promiscuity. This model correctly classified 94% of 111 compds.-- 47 aggregators and 64 nonaggregators-- that have been studied for this effect. To evaluate the model, it was used to predict the behavior of 75 drugs not previously investigated for aggregation. Several preliminary points emerge. Most drugs are not promiscuous, even at high concns. Nevertheless, at high enough concns. (20-400  $\mu$ M), some drugs can aggregate and act promiscuously, suggesting that aggregation may be common among small mols. at micromolar concns., at least in biochem. buffers.....

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:311364 HCAPLUS

DOCUMENT NUMBER: 130:335011

TITLE: A method for separating non-proteinaceous substances from proteinaceous substances for subsequent processing

INVENTOR(S): Akerman, Satu; Paronen, Petteri; Akerman, Kari; Jarvinen, Kristiina; Kontturi, Kyosti; Nasman, Jan; Svarfvar, Bror; Urtti, Arto; Viinikka, Pasi

PATENT ASSIGNEE(S): Finland

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9923487	A1	19990514	WO 1998-FI852	19981103
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9910342	A	19990524	AU 1999-10342	19981103
PRIORITY APPLN. INFO.:			FI 1997-4124	A 19971104
			WO 1998-FI852	W 19981103

AB The present invention is directed to a simple but efficient method for separating non-proteinaceous substances, such as drugs and nucleic acids from proteinaceous substances for subsequent monitoring and evaluation. The non-proteinaceous substances are captured by an environmentally sensitive solid carrier under physiol. conditions and released under non-physiol. conditions with a solvent, which is compatible with or used in subsequent steps. The solid carriers are provided in the form of membranes, sheets, sticks, plates, test tubes, microplates or as beads or granules attached to a further solid support. The surface of said carriers are covered with capturing residues, which are sensitive to changes in the environmental conditions, e.g. pH or ionic strength. Said residues are responsible for binding and release of drugs or nucleic acids and allows their easy and rapid separation from proteins. Test kits including said solid carriers as well as their applications are also disclosed. Vinylpyridine-grafted

poly(vinylidene fluoride) membranes (preparation given) were used to sep. DNA from digest solution. Bound DNA was released with methanol for spectrophotometric anal.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:464546 HCAPLUS  
DOCUMENT NUMBER: 125:96152  
TITLE: Pharmaceutical granules comprising lamotrigine  
INVENTOR(S): Hiskett, Simon Philip; Taylor, Susan Ann  
PATENT ASSIGNEE(S): Wellcome Foundation Ltd., UK  
SOURCE: PCT Int. Appl., 26 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9617611	A1	19960613	WO 1995-GB2865	19951207
W:	AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2207284	A1	19960613	CA 1995-2207284	19951207
AU 9641211	A	19960626	AU 1996-41211	19951207
AU 696406	B2	19980910		
EP 797441	A1	19971001	EP 1995-939352	19951207
EP 797441	B1	20020227		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV			
CN 1174505	A	19980225	CN 1995-197473	19951207
HU 77367	A2	19980330	HU 1997-2196	19951207
BR 9509975	A	19980609	BR 1995-9975	19951207
JP 10510255	T	19981006	JP 1995-517420	19951207
JP 2977284	B2	19991115		
RU 2160106	C2	20001210	RU 1997-111870	19951207
AT 213633	T	20020315	AT 1995-939352	19951207
ES 2172600	T3	20021001	ES 1995-939352	19951207
FI 9702434	A	19970609	FI 1997-2434	19970606
NO 9702623	A	19970806	NO 1997-2623	19970606
US 5861179	A	19990119	US 1997-849070	19970626
PRIORITY APPLN. INFO.:			GB 1994-24766	A 19941207
			WO 1995-GB2865	W 19951207

AB A pharmaceutical formulation comprises: (a) from 0.5 to 50% by weight of lamotrigine or a pharmaceutically acceptable acid addition salt thereof, (b) from 15 to 50% by weight of lactose, (c) from 15 to 50% by weight of starch, (d) from 0.5 to 15% by weight of crystalline cellulose, and (e) from 5 to 15% by weight of polyvinylpyrrolidone, and which is in the form of a free-flowing powder of granules having the following properties: (1) no granules have a

particle size of greater than 850  $\mu\text{m}$ , (2) at least 90% by weight of the granules have a particle size of from 75 to 850  $\mu\text{m}$ , (3) the granules disintegrate within 30 min according to the Disintegration Test of The Pharmacopoeia of Japan, twelfth edition, 1991, and (i.v.) of at least 90% by weight of the lamotrigine or lamotrigine salt in the granules dissolves within 30 min when the granules are subjected to the dissoln. test, method 2 (paddle method) of the Pharmacopoeia of Japan, twelfth edition, 1991. Formulation of various granules are disclosed.

L13 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:440156 HCAPLUS

DOCUMENT NUMBER: 119:40156

TITLE: New method for the determination of four antiepileptic drugs in human plasma by high performance liquid chromatography

AUTHOR(S): Meyler, M.; Kelly, M. T.; Smyth, M. R.

CORPORATE SOURCE: Sch. Chem. Sci., Dublin City Univ., Dublin, Ire.

SOURCE: Chromatographia (1993), 36, 27-32

CODEN: CHRGB7; ISSN: 0009-5893

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The concurrent administration of several antiepileptic drugs for the treatment of seizure disorders has become common practice. Lamotrigine is a new antiepileptic given in combination with other antiepileptic drugs, but which is not routinely measured in clin. labs. An isocratic high-performance liquid chromatog. method is described for the simultaneous measuring lamotrigine, carbamazepine, phenobarbital and phenytoin within 10 min. The chromatog. system used an Hichrom Spherisorb CN column (20 cm x 4 mm, i.d., 5  $\mu\text{m}$  particle size), a  $\mu\text{Bondapak CN}$  precolumn, and a mobile phase consisting of methanol : acetonitrile : 5 mM sodium acetate (5 : 20 75: by volume, pH adjusted to 6.3 with acetic acid). BWA 725C was used as internal standard The drugs were extracted from 200  $\mu\text{L}$

of

plasma with Et acetate, acetonitrile and 5 mM sodium acetate. After evaporation of the organic layer and reconstitution in mobile phase, 25  $\mu\text{L}$  of extract was eluted with mobile phase at a flow rate of 1.2 mL/min. The eluted drugs were detected by their absorption at 205 nm and quantified from their peak heights. The method was found to be rapid, relatively simple to perform and sufficiently sensitive to determine each drug over its entire therapeutic range. Lower limits of detection varied from 50-100 ng/mL, absolute recoveries from 93-98%, and mean intra- and inter-assay CVs were <3.0%.

L13 ANSWER 22 OF 22 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:93715 HCAPLUS

DOCUMENT NUMBER: 118:93715

TITLE: A liquid chromatographic assay using a high-speed column for the determination of lamotrigine, a new antiepileptic drug, in human plasma

AUTHOR(S): Fazio, A.; Artesi, C.; Russo, M.; Trio, R.; Oteri, G.; Pisani, F.

CORPORATE SOURCE: 1st Neurol. Clin., Univ. Messina, Messina, Italy

SOURCE: Therapeutic Drug Monitoring (1992), 14(6), 509-12  
CODEN: TDMODV; ISSN: 0163-4356

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A sensitive, specific and rapid liquid-chromatog. method for the determination of



the new antiepileptic drug lamotrigine (LTG) in human plasma is described. The method involves the use of a com. available 3- $\mu$ m particle size normal-phase column and a microflow-cell-equipped UV detector. Extraction is carried out with Et acetate after alkalization on a 100- $\mu$ L plasma sample containing LTG and 3,5-diamino-6-(2-methoxyphenyl)-1,2,4-triazine as internal standard. The residue is reconstituted with 50  $\mu$ L of ethanol, and 5  $\mu$ L of the final solution is injected into the column. Elution is carried out at 34° using n-hexane/absolute ethanol/35% ammonia (80:20:0.25 by volume) as mobile phase at a flow rate of 2.0 mL/min. Detection is at 313 nm. The chromatog. separation requires <3 min and the sensitivity limit is <0.01 mg/L. Recovery is 88-96.2%, whereas within-day and day-to-day coeffs. of variation are between 4.1 and 7.7%.

=> d his

(FILE 'HOME' ENTERED AT 13:03:43 ON 29 NOV 2007)

FILE 'REGISTRY' ENTERED AT 13:03:52 ON 29 NOV 2007

L1 1 S 84057-84-1/RN

FILE 'HCAPLUS' ENTERED AT 13:04:14 ON 29 NOV 2007

L2 1461 S L1  
L3 278076 S PARTICLE (A) SIZE  
L4 35036 S SPECIFIC (A) SURFACE (A) AREA  
L5 5893 S L3 AND L4  
L6 0 S L5 AND L2  
L7 1 S L4 AND L2  
L8 12 S L2 AND L3

FILE 'STNGUIDE' ENTERED AT 13:06:40 ON 29 NOV 2007

L9 0 S PARTICLE (A) DIAMETER  
L10 0 S L1 AND PARTICLE?

FILE 'HCAPLUS' ENTERED AT 13:12:23 ON 29 NOV 2007

L11 36158 S PARTICLE (A) DIAMETER  
L12 2 S L11 AND L1  
L13 22 S L1 AND PARTICLE?